News
AKBA
1.235
-3.52%
-0.045
Weekly Report: what happened at AKBA last week (0720-0724)?
Weekly Report · 1d ago
Monopar adds ex-KalVista CCO Nicole Sweeny to board
PUBT · 07/20 12:02
Weekly Report: what happened at AKBA last week (0713-0717)?
Weekly Report · 07/20 09:42
Akebia: Vafseo Gains Traction, But It's Still A Show-Me Story (Rating Downgrade)
Seeking Alpha · 07/14 11:30
Weekly Report: what happened at AKBA last week (0706-0710)?
Weekly Report · 07/13 09:44
Weekly Report: what happened at AKBA last week (0629-0703)?
Weekly Report · 07/06 09:45
Insider Shake-Up: GC, Akebia, Perion, Paychex, Arqit
TipRanks · 07/04 13:01
AKEBIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/02 20:05
Top Akebia Executive Makes Notable Insider Stock Move
TipRanks · 07/02 02:03
Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 07/01 11:57
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
Benzinga · 07/01 11:48
Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Akebia Therapeutics (AKBA)
TipRanks · 07/01 10:20
Akebia announces VOICE trial met predefined stopping criteria
TipRanks · 06/30 12:31
Akebia Reports Positive Interim VOICE Trial Results
TipRanks · 06/30 12:30
Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study After Planned Interim Analysis Based On Recommendation From Independent Data Monitoring Committee, Trial Steering Committee
Benzinga · 06/30 12:09
AKEBIA THERAPEUTICS - USRC KIDNEY RESEARCH STOPS VOICE TRIAL AFTER INTERIM ANALYSIS SHOWS IMPROVED SAFETY WITH VAFSEO
Reuters · 06/30 12:07
AKEBIA THERAPEUTICS - NO SIGNIFICANT DIFFERENCE IN MORTALITY: VAFSEO 8.77% VS ESA 8.78% PER 100 PATIENT-YEARS
Reuters · 06/30 12:07
Akebia says interim VOICE trial analysis shows Vafseo cuts death-or-hospitalization risk vs ESA
PUBT · 06/30 12:05
Weekly Report: what happened at AKBA last week (0622-0626)?
Weekly Report · 06/29 09:42
Akebia Shareholders Approve Governance Measures and Share Increase
TipRanks · 06/22 21:35
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.